Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review

被引:7
作者
Liu, Peng [1 ]
Tan, Fengbo [1 ]
Liu, Heli [1 ]
Ge, Jie [1 ]
Liu, Sheng [1 ]
Lei, Tianxiang [1 ]
Zhao, Xianhui [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha 410008, Hunan, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
关键词
gastrointestinal stromal tumor; skin metastasis; tyrosine kinase inhibitors; SUBCUTANEOUS METASTASIS; IMATINIB MESYLATE; CUTANEOUS METASTASES; TYROSINE KINASE; FREE SURVIVAL; KIT; MUTATIONS; THERAPY; STOMACH; RECURRENCE;
D O I
10.2147/CMAR.S261823
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastrointestinal stromal tumors (GISTs) extremely and rarely metastasize to the skin, and such metastases have not been well characterized. Methods: Retrospective analysis of clinicopathological data of patients with skin metastasis of a GIST (SM-GIST) admitted to Xiangya Hospital (Changsha, Hunan, China) and literature review were conducted. Results: Including our 4 cases, a total of 17 cases have been reported to date. The mean age of the patients was 55.4 years (2970 years) and there was not sex predominance (male 10 and female 7). Primary tumors were often located in the stomach (n=9), duodenum (n=2) and small bowel (n=2). Meanwhile, SM-GIST mainly occurred in head and face (n=6), extremities (n=6), followed by abdomen wall (n=5), back (n=3) and chest (n=2). Mutation analysis revealed that the frequency of wild-type GIST (WT-GIST), exon 9, 11 and 13 mutations was 6, 1, 4 and 1, respectively. The average time to SM-GIST was 4.22 years, specifically 4.59 years in gastric and 3.8 years in non-gastric. Moreover, for the resection only group (including chemotherapy), such average time was 3.63 years, while for the combined group (resection and tyrosine kinase inhibitors (TKIs)), it was about 4.74 years. The mean survival was approximately 6.2 years. However, after the diagnosis of SM-GIST, survival was only about 1.69 years. Conclusion: SM-GIST is a rare malignant condition. Non-gastric GIST, surgery without TKIs, high invasiveness and tumor burden, and molecular subtype (mutation in exon 9, 11 and wild-type) may be conducive to the development of SM-GIST. Additionally, it is also a sign of poor prognosis.
引用
收藏
页码:7681 / 7690
页数:10
相关论文
共 44 条
[41]   Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial [J].
Verweij, J ;
Casali, PG ;
Zalcberg, J ;
LeCesne, A ;
Reichardt, P ;
Blay, JY ;
Issels, R ;
van Oosterom, A ;
Hogendoorn, PCW ;
Van Glabbeke, M ;
Bertulli, R ;
Judson, I .
LANCET, 2004, 364 (9440) :1127-1134
[42]   Gastrointestinal Stromal Tumors [J].
von Mehren, Margaret ;
Joensuu, Heikki .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (02) :136-+
[43]   Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors: A Series of 5 Cases With Molecular Analysis [J].
Wang, Wei-Lien ;
Hornick, Jason L. ;
Mallipeddi, Raj ;
Zelger, Bettina G. ;
Rother, Joshua D. ;
Yang, Dan ;
Lev, Dina C. ;
Trent, Jonathan C. ;
Prieto, Victor G. ;
Brenn, Thomas ;
Calonje, Eduardo ;
Lazar, Alexander J. F. .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2009, 31 (03) :297-300
[44]   The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status [J].
West, RB ;
Corless, CL ;
Chen, X ;
Rubin, BP ;
Subramanian, S ;
Montgomery, K ;
Zhu, S ;
Ball, CA ;
Nielsen, TO ;
Patel, R ;
Goldblum, JR ;
Brown, PO ;
Heinrich, MC ;
Van de Rijn, M .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (01) :107-113